Related Experiment Video
Updated: Aug 30, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
RhoA expression is not a critical determinant in hypertension evolution in salt-sensitive Dahl rats
Takeshi Yoneda1, Yasuki Kihara, Hiroyuki Takenaka
1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan.
Background:
The Rho/Rho kinase pathway plays an important role in regulation of vascular smooth muscle cell contraction and is involved in the pathogenesis of hypertension. However, little is known about the role of this pathway in the evolution of salt-sensitive hypertension and vascular remodeling. The aim of this study was to examine whether the age-dependent surge of blood pressure after exposure to a high salt-containing diet, which is well-established for Dahl salt-sensitive rats, is primarily regulated by the level of expression of RhoA in arterial vessels.
Material/Methods:
We examined Dahl salt-sensitive rats at 3 weeks, 6 weeks, and 9 weeks of age (n=10, each). In each group, animals were switched to being fed a diet containing 8% NaCl from one containing 0.3% NaCl. After 7 days, mRNA and protein levels of RhoA from the thoracic aorta were quantified.
Results:
At the time of examination, increases in systolic blood pressure were significantly different depending on the age at which the high salt diet was initiated. The % increases were 34+/-3% (3-weeks), 20+/-2% (6-weeks), and 13+/-2% (9-weeks). Despite these differing changes in blood pressure, mRNA and protein levels of RhoA in the arteries did not differ among the groups.
Conclusions:
RhoA expression and activity appear not to be the critical determinant of the surge in hypertension when Dahl salt-sensitive rats are exposed to salt-rich diets. Hence, the age-dependent salt-sensitivity must be mediated by alternative pathways.
Related Concept Videos
Responses to Salt Stress
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

